Insulet is primarily engaged in the development, manufacture and sale of its proprietary Omnipod® System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of the following: the Omnipod Insulin Management System, which features a disposable tubeless Omnipod device (POD), and its handheld Personal Diabetes Manager (PDM); and the Omnipod DASH Insulin Management System, which features a secure Bluetooth enabled Pod and PDM with a color touch screen user interface supported by smartphone connectivity. Co. has partnered with pharmaceutical and biotechnology companies for the delivery of subcutaneous drugs across other therapeutic areas. The PODD stock yearly return is shown above.
The yearly return on the PODD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PODD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|